Iovance Biotherapeutics
IOVA· Manufacturing· Fiscal year ends in December
CEO pay in FY2025Stock -63.1% in FY2025
Frederick G. Vogt, Ph.D., J.D. is the CEO of Iovance Biotherapeutics and was paid $1.9M in FY2025 (Dec), down 83%.
Pay$100 in the stock at the end of FY20 → $6
Executives7
See all- 1Daniel KirbyChief Commercial OfficerFY2025
- 2Frederick G. Vogt, Ph.D., J.D.Interim Chief Executive Officer and President, General CounselFY2025
- 3Corleen RocheChief Financial OfficerFY2025
- 4Raj K. Puri, M.D., Ph.D.Chief Regulatory OfficerFY2025
- 5Igor Bilinsky, Ph.D.Chief Operating OfficerFY2025
- 6Matthew W. RosinackInterim Principal Financial Officer and Principal Accounting OfficerFY2025
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allIovance Biotherapeutics paid its 7 named executives $9.4M in total in FY2025 (Dec). CEO Frederick G. Vogt, Ph.D., J.D. was paid $1.9M of that.
| Name | |||
|---|---|---|---|
| Daniel KirbyChief Commercial Officer | Not disclosed | Not disclosed | |
| Frederick G. Vogt, Ph.D., J.D.Interim Chief Executive Officer and President, General Counsel | |||
| Corleen RocheChief Financial Officer | Not disclosed | Not disclosed | |
| Raj K. Puri, M.D., Ph.D.Chief Regulatory Officer | Not disclosed | ||
| Igor Bilinsky, Ph.D.Chief Operating Officer | |||
| Matthew W. RosinackInterim Principal Financial Officer and Principal Accounting Officer | Not disclosed | Not disclosed |
of each named executive, from the Summary Compensation Table of each proxy.
Peers16
See allThe comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.
Board2
See all- Wayne P. RothbaumDirector · 9 yr on the boardIndependentCompensation—Paid as an executive
- Athena CountouriotisDirector · 6 yr on the boardIndependentCompensation—Paid as an executive
The board of the latest proxy (FY2025).
Activity
Filings6
See all| Proxy statement | DEF 14A | Apr 28, 2026 | FY2025 |
| Annual report | 10-K | Feb 24, 2026 | FY2025 |
| Proxy statement | DEF 14A | Apr 28, 2025 | FY2024 |
| Annual report | 10-K | Feb 27, 2025 | FY2024 |
| Proxy statement | DEF 14A | Apr 29, 2024 | FY2023 |
| Annual report | 10-K | Feb 28, 2024 | FY2023 |